How challenging can it be to treat Behçet uveitis?
| Autor: | Oray M; Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Cebeci Z; Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Kir N; Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Tugal-Tutkun I; Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society [Saudi J Ophthalmol] 2022 Dec 27; Vol. 36 (4), pp. 397-399. Date of Electronic Publication: 2022 Dec 27 (Print Publication: 2022). |
| DOI: | 10.4103/sjopt.sjopt_74_22 |
| Abstrakt: | A 20-year-old male Behçet uveitis (BU) patient presented with visual acuities (VAs) of hand movement in OD and counting fingers at 1 m in OS following treatment with corticosteroid monotherapy elsewhere. He had active intraocular inflammation OU along with macular hole and retinal detachment in OS. Infliximab (IFX) was started and vitreoretinal surgery was performed. He had infusion reaction with IFX, hepatotoxicity and depression with interferon, and resistance to adalimumab and tocilizumab therapies. Cytomegalovirus retinitis developed in OD following intravitreal dexamethasone implant and endophthalmitis developed in OS. At the 33 rd month of follow-up, the patient was in clinical remission; however, there was persistent angiographic inflammation under certolizumab pegol, cyclosporine, mycophenolate mofetil, and low-dose prednisolone treatment. The left eye was phthisical and VA was 0.4 in OD. Immunomodulatory treatment is given based on the severity of inflammation in BU and needs to be closely monitored for efficacy and adverse effects. Competing Interests: There are no conflicts of interest. (Copyright: © 2022 Saudi Journal of Ophthalmology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|